The FDA has approved finerenone (Kerendia, Bayer) for the treatment of adults with chronic kidney disease (CKD) associated with type 1 diabetes (T1D). The once-daily oral nonsteroidal mineralocorticoid receptor agonist reduces the urinary albumin-to-creatinine ratio (UACR), which is expected to lower the risk for sustained estimated glomerular filtration rate (eGFR) decline and end-stage kidney disease …
Read More
FDA Okays Finerenone for CKD in Adults With Type 1 Diabetes
